Quantcast

Latest Certolizumab pegol Stories

2008-10-08 09:00:00

BURLINGTON, ONTARIO--(Marketwire - Oct. 8, 2008) - UCB Pharma Canada today announced data presented at the American College of Gastroenterology (ACG) Scientific Meeting, in Orlando, Florida, from two studies demonstrating that CIMZIA(R) (certolizumab pegol) - the only PEGylated anti-TNF (Tumor Necrosis Factor alpha) - provides sustained improvement in symptoms with stable dosing for adult patients suffering from moderate-to-severe Crohn's disease (CD). A third study presented by UCB provided...

2008-10-07 09:00:56

UCB, a Belgium-based biopharmaceutical and specialty chemical company, has presented positive data from a large, prospective study investigating endoscopic improvement in Crohn's disease with a biologic compound. The data showed that Cimzia (certolizumab pegol) - the only PEGylated anti-TNF alpha (tumor necrosis factor alpha) - significantly improved endoscopic lesions and induced endoscopic response (as assessed by the Crohn's Disease Endoscopic Index of Severity (CDEIS)) within 10 weeks...

2008-10-07 09:00:14

ORLANDO, Fla. Oct. 7 /PRNewswire-FirstCall/ -- Data from two studies presented this week by UCB at the American College of Gastroenterology (ACG) Annual Meeting demonstrate that CIMZIA(R) (certolizumab pegol) - the only PEGylated anti-TNF alpha (Tumor Necrosis Factor alpha) - provides sustained improvement in symptoms with stable dosing for adult patients suffering from moderate to severe Crohn's disease (CD). A third study presented by UCB provided an estimated comparison of treatment costs...

2008-10-06 09:00:09

ORLANDO, Fla., Oct. 6 /PRNewswire/ -- UCB today presented data from a large, prospective study investigating endoscopic improvement in Crohn's disease (CD) with a biologic compound. The data presented at the American College of Gastroenterology Annual Scientific Meeting demonstrates that CIMZIA(R) (certolizumab pegol) -- the only PEGylated anti-TNF alpha (Tumor Necrosis Factor alpha) -- significantly improved endoscopic lesions and induced endoscopic response (as assessed by the Crohn's...

2008-07-07 06:00:26

UCB's certolizumab is marketed under the brand name Cimzia. The submission for rheumatoid arthritis treatment, if accepted, will make it the first and only PEGylated, Fc-Free anti-TNF (tumor necrosis factor) alpha biologic therapy in Europe. Certolizumab has some advantages over current treatments but its late arrival on the market will work against it as it tries to claim market share. UCB announced on July 1, 2008 that a Marketing Authorization Application (MAA) has been submitted to the...

2008-07-01 03:00:09

The European marketing authorisation application for Cimzia(R) has been filed. Subject to approval, Cimzia(R) will be the first and only PEGylated, Fc-Free anti-TNF (Tumour Necrosis Factor alpha) biologic therapy. BRUSSELS, BELGIUM - July 1st 2008 - 7:00 am CET - UCB today announced that a Marketing Authorisation Application (MAA) has been submitted to the European Medicines Agency (EMEA) requesting the approval of Cimzia(R) (certolizumab pegol) as a subcutaneous treatment for adults with...

2005-10-18 09:02:44

LONDON (Reuters) - UCB's experimental drug Cimzia is effective and well-tolerated in treating Crohn's disease, a chronic inflammatory disorder of the digestive tract, researchers said on Tuesday. The Belgian drug maker said it now planned to file the drug for regulatory approval in both the United States and Europe during the first quarter of 2006. Cimzia, or CDP870, is a key product from UCB, which is seeking new sources of sales growth ahead of the loss of U.S. patent protection...


Word of the Day
cenobite
  • One of a religious order living in a convent or in community; a monk: opposed to anchoret or hermit (one who lives in solitude).
  • A social bee.
This word comes from the Latin 'coenobium,' convent, which comes from the Greek 'koinobios,' living in community.
Related